Cite

HARVARD Citation

    Powles, T. et al. (2023). Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma – Authors' reply. Lancet oncology. 24 (1), pp. e1-e2. [Online]. 
  
Back to record